Latest Intelligence

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

Type Product title / description Pub Price
NewsWire
NewsWire

3-Dimensional awarded patent covering protease inhibitors associated with blood clotting

Published By MarketLine
20 Sep 2001
NewsWire
NewsWire

3-Dimensional Pharmaceuticals and Bristol-Myers Squibb modify drug discovery alliance

Published By MarketLine
19 Dec 2000
NewsWire
NewsWire

3-Dimensional Pharmaceuticals and Johnson & Johnson enter drug discovery alliance

3-Dimensional Pharmaceuticals has formed a drug discovery alliance to discover and optimize small molecule drug leads directed to genomics targets identified by Johnson & Johnson Pharmaceutical Research & Development.

Published By MarketLine
08 Jan 2002
NewsWire
NewsWire

3-Dimensional Pharmaceuticals Announces Financial Results For The Quarter And Year Ended December 31, 2000

Published By MarketLine
27 Feb 2001
NewsWire
NewsWire

3-Dimensional Pharmaceuticals Announces Financial Results For the Quarter Ended March 31, 2001

Published By MarketLine
26 Apr 2001
NewsWire
NewsWire

3-Dimensional Pharmaceuticals extends research funding on thrombin collaboration

3-Dimensional Pharmaceuticals is to extend its thrombin research collaboration with Centocor and Johnson & Johnson Pharmaceutical R&D, both members of the Johnson & Johnson family of companies.<BR /><BR />

Published By MarketLine
04 Feb 2003
NewsWire
NewsWire

3-Dimensional Pharmaceuticals licenses GlaxoSmithKline's investigational low blood platelet treatment

3-Dimensional Pharmaceuticals has entered into an exclusive licensing agreement with GlaxoSmithKline, giving it worldwide development, marketing and distribution rights to GlaxoSmithKline's pre-Investigational New Drug application compound GW 395058 for the prevention and treatment of thrombocytopenia, or low blood platelet count.<BR />

Published By MarketLine
08 Jan 2002
NewsWire
NewsWire

3-V Biosciences announces positive preclinical data from solid tumor studies

3-V Biosciences, Inc., a biopharmaceutical company, has announced positive data from preclinical studies of the company's novel fatty acid synthase, or FASN, inhibitors.

Published By MarketLine
30 Oct 2013
NewsWire
NewsWire

3-V Biosciences appoints new CEO

3-V Biosciences, a biopharmaceutical company, has appointed Merdad Parsey as new CEO.

Published By MarketLine
04 Oct 2010
NewsWire
NewsWire

3-V Biosciences appoints new chief business officer

3-V Biosciences, Inc., a privately-held biopharmaceutical company, has appointed Stephen Brady as chief business officer.

Published By MarketLine
11 Feb 2011

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | ... | » »|

No help is available.